Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S was founded in 2020 and is based in Copenhagen, Denmark.
Metrics to compare | CESSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCESSAPeersSector | |
---|---|---|---|---|
P/E Ratio | −12.3x | 2.1x | −0.5x | |
PEG Ratio | −0.27 | −0.05 | 0.00 | |
Price/Book | 45.5x | 2.3x | 2.6x | |
Price / LTM Sales | 161.1x | 1.4x | 3.3x | |
Upside (Analyst Target) | - | 163.2% | 43.5% | |
Fair Value Upside | Unlock | 5.8% | 6.9% | Unlock |